Exhibit 10.4
CONSULTING AGREEMENT
This Consulting Agreement (this “Agreement”) dated as of May 10, 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Michael Cruse (“Consultant”).
RECITALS
WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and
WHEREAS, the Company wishes to retain Consultant to perform consulting services and fulfill certain related duties and obligations under the terms and conditions of this Agreement contingent upon and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger by and among the Company, Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc. (the “Merger Agreement”).
NOW, THEREFORE, in consideration of (a) the mutual covenants and agreements set forth in this Agreement, and (b) other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:
-2-
-3-
-4-
[SIGNATURES ON FOLLOWING PAGE]
-5-
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
Reneo Pharmaceuticals, Inc. | ||
|
|
|
|
|
|
|
|
|
By: |
| /s/ Gregory J. Flesher |
|
| Gregory J. Flesher |
|
| President and CEO |
|
|
/s/ Michael Cruse |
Michael Cruse |
Signature Page to Cruse Consulting Agreement